Asymmetric Total Syntheses of Platensimycin

摘要

The disclosure of platensimycin ((-)-1, Scheme 1) and its impressive antibacterial properties has generated considerable interest in the scientific and medical community. The unique mechanism of action of platensimycin, which involves the inhibition of the bacterial biosynthesis of fatty acids through the binding of platensimycin to the acyl-enzyme intermediate of the elongation-condensing enzyme -ketoacyl-acyl carrier protein synthase I/II (FabF/B), has raised hopes for a powerful new therapy against drug-resistant bacteria.